Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.
cardiotoxicity
lymphoma
non-Hodgkin
survivorship
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
revised:
21
02
2023
received:
19
09
2022
accepted:
22
02
2023
pmc-release:
01
07
2024
medline:
9
6
2023
pubmed:
28
3
2023
entrez:
27
3
2023
Statut:
ppublish
Résumé
To describe the incidence of cardiotoxicity in patients with anthracycline exposure who subsequently receive EPOCH for non-Hodgkin lymphoma (NHL). We conducted a retrospective cohort study of adults with anthracycline exposure who subsequently received EPOCH for NHL at Memorial Sloan Kettering Cancer Center. The primary outcome was cumulative incidence of arrhythmia, heart failure (HF), left ventricular (LV) dysfunction, or cardiac death. Among 140 patients, most had diffuse large B-cell lymphoma. Inclusive of EPOCH, median cumulative doxorubicin-equivalent dose was 364 mg/m In this retrospective cohort, representing the largest experience in this setting with extended follow-up, cumulative incidence of cardiac events was low. Rates of LV dysfunction or HF were particularly low, suggesting infusional administration may mitigate risk despite prior exposure.
Identifiants
pubmed: 36971022
doi: 10.1111/ejh.13971
pmc: PMC10634315
mid: NIHMS1939811
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
Anthracyclines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
96-102Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIH HHS
Pays : United States
Informations de copyright
© 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
Références
Mayo Clin Proc. 2008 Jun;83(6):679-86
pubmed: 18533085
Ann Oncol. 2006 Apr;17(4):614-22
pubmed: 16423847
Minerva Med. 1989 Mar;80(3):305-7
pubmed: 2541379
J Natl Compr Canc Netw. 2021 Nov;19(11):1218-1230
pubmed: 34781267
Blood. 2002 Apr 15;99(8):2685-93
pubmed: 11929754
Circulation. 2016 Jun 21;133(25):2671-86
pubmed: 27324362
Ann Intern Med. 1982 Feb;96(2):133-9
pubmed: 7059060
J Clin Oncol. 2017 Mar 10;35(8):893-911
pubmed: 27918725
J Clin Oncol. 2017 Dec 1;35(34):3837-3843
pubmed: 28922087
J Natl Compr Canc Netw. 2020 Nov 02;18(11):1460-1467
pubmed: 33152703
Ann Oncol. 2020 Feb;31(2):171-190
pubmed: 31959335
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
Pediatrics. 2008 Feb;121(2):e387-96
pubmed: 18187811
Clin Cardiol. 1992 Feb;15(2):122-5
pubmed: 1371094
Tumori. 1984 Jun 30;70(3):235-6
pubmed: 6588670
Lancet. 1981 May 16;1(8229):1111
pubmed: 6112479
Cancer Chemother Rep. 1975 Sep-Oct;59(5):887-8
pubmed: 1203893
J Clin Oncol. 2002 Mar 1;20(5):1215-21
pubmed: 11870163
Cancer. 2003 Jun 1;97(11):2869-79
pubmed: 12767102
Curr Cardiol Rev. 2011 Nov;7(4):214-20
pubmed: 22758622
Circulation. 2003 Aug 26;108(8):977-82
pubmed: 12912813
Ann Intern Med. 1979 Nov;91(5):710-7
pubmed: 496103
Semin Oncol. 2001 Aug;28(4 Suppl 12):2-7
pubmed: 11552224
J Clin Oncol. 2000 Nov 1;18(21):3633-42
pubmed: 11054436
J Clin Oncol. 2004 May 15;22(10):1864-71
pubmed: 15143078
J Clin Oncol. 1993 Aug;11(8):1573-82
pubmed: 7687667